Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion

Malignant pleural mesothelioma (MPM) is a deadly disease with few systemic treatment options. One potential therapeutic target, the non–receptor tyrosine kinase c-Src, causes changes in proliferation, motility, invasion, survival, and angiogenesis in cancer cells and may be a valid therapeutic target in MPM. To test this hypothesis, we determined the effects of c-Src inhibition in MPM cell lines and examined c-Src expression and activation in tissue samples. We analyzed four MPM cell lines and found that all expressed total and activated c-Src. Three of the four cell lines were sensitive by in vitro cytotoxicity assays to the c-Src inhibitor dasatinib, which led to cell cycle arrest and increased apoptosis. Dasatinib also inhibited migration and invasion independent of the cytotoxic effects, and led to the rapid and durable inhibition of c-Src and its downstream pathways. We used immunohistochemical analysis to determine the levels of c-Src expression and activation in 46 archived MPM tumor specimens. The Src protein was highly expressed in tumor cells, but expression did not correlate with survival. However, expression of activated Src (p-Src Y419) on the tumor cell membrane was higher in patients with advanced-stage disease; the presence of metastasis correlated with higher membrane (P = 0.03) and cytoplasmic (P = 0.04) expression of p-Src Y419. Lower levels of membrane expression of inactive c-Src (p-Src Y530) correlated with advanced N stage (P = 0.02). Activated c-Src may play a role in survival, metastasis, and invasion of MPM, and targeting c-Src may be an important therapeutic strategy. [Mol Cancer Ther 2007;6(7):1962–72]

[1]  J. Trevino,et al.  Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. , 2005, Cancer research.

[2]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[3]  A. Andres,et al.  Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. , 1994, Oncogene.

[4]  D. Quinn,et al.  Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance , 2005, Clinical Cancer Research.

[5]  L. Naldini,et al.  Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. , 2004, Cancer cell.

[6]  F. Lee,et al.  Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. , 2006, The American journal of pathology.

[7]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[8]  J. Trevino,et al.  AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes , 2005, Molecular Cancer Therapeutics.

[9]  Jie Zhang,et al.  SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. , 2007, The American journal of pathology.

[10]  T. Nakano,et al.  Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells , 2006, Apoptosis.

[11]  D. Anderson,et al.  Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. , 1999, Molecular cell.

[12]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[13]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[14]  A. Casalini,et al.  Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma , 2001, The Journal of pathology.

[15]  J. Campisi,et al.  Kinetics of G1 transit following brief starvation for serum factors. , 1984, Experimental cell research.

[16]  Hedy L Kindler,et al.  Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. , 2004, Lung cancer.

[17]  E. Gabrielson,et al.  Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. , 1987, Cancer research.

[18]  R. K. Bright,et al.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.

[19]  T. Yeatman,et al.  Role of Src expression and activation in human cancer , 2000, Oncogene.

[20]  S. Jhanwar,et al.  Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK , 2006, Oncogene.

[21]  I. Downie,et al.  Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. , 2001, American journal of clinical pathology.

[22]  E. van Marck,et al.  Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression , 1999, The Journal of pathology.

[23]  R. Jove,et al.  Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.

[24]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Moshe Talpaz,et al.  Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.

[26]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[27]  M. Kinch,et al.  Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation , 2000, Nature Cell Biology.

[28]  M. Hendrix,et al.  Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. , 2007, The American journal of pathology.

[29]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[30]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[31]  P. Zhang,et al.  c-src activating mutation analysis in Chinese patients with colorectal cancer. , 2005, World journal of gastroenterology.

[32]  P. Schwartzberg,et al.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.

[33]  M. Roncalli,et al.  Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients , 2001, British Journal of Cancer.

[34]  J. Folkman,et al.  Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity , 2005, Clinical Cancer Research.

[35]  T. Dorai,et al.  Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. , 1994, Molecular pharmacology.

[36]  K. Müller,et al.  Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma , 1999, Virchows Archiv.

[37]  J. Weyler,et al.  EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA , 1997, The Journal of pathology.

[38]  J. Cheng,et al.  Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. , 2005, Cancer research.

[39]  T. le Chevalier,et al.  Adjuvant treatment of lung cancer: current status and potential applications of new regimens. , 2004, Lung cancer.

[40]  P. Scalia,et al.  Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops , 2003, International journal of cancer.

[41]  Timothy J. Yeatman,et al.  Activating SRC mutation in a subset of advanced human colon cancers , 1999, Nature Genetics.

[42]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[43]  A. Pandey,et al.  Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. , 1995, Science.

[44]  F. Johnson,et al.  SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. , 2007, Anti-cancer agents in medicinal chemistry.

[45]  L. Ellis,et al.  HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas , 2005, Oncogene.

[46]  K. Gibson,et al.  ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.

[47]  J. Trevino,et al.  c-Src Regulates Constitutive and EGF-mediated VEGF Expression in Pancreatic Tumor Cells Through Activation of Phosphatidyl Inositol-3 Kinase and p38 MAPK , 2005, Pancreas.

[48]  M. Halpern,et al.  Induction of a diffuse mesothelioma in chickens by intraperitoneal inoculation of v-src DNA. , 1991, Virology.

[49]  T. H. van der Kwast,et al.  EXPRESSION OF PLATELET‐DERIVED GROWTH FACTOR (PDGF) AND PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA IN VITRO AND IN VIVO , 1996, The Journal of pathology.

[50]  G. Giaccone,et al.  Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  M. R. Rippo,et al.  Induction of Stem Cell Factor/c-Kit/Slug Signal Transduction in Multidrug-resistant Malignant Mesothelioma Cells* , 2004, Journal of Biological Chemistry.

[52]  J. Stamos,et al.  The Sema domain of Met is necessary for receptor dimerization and activation. , 2004, Cancer cell.

[53]  V. Levin.  Basis and importance of Src as a target in cancer. , 2004, Cancer treatment and research.

[54]  J. Herndon,et al.  Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.

[55]  D. Hicklin,et al.  Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  S. Mutsaers,et al.  Cytokine regulation of mesothelial cell proliferation in vitro and in vivo. , 1997, European journal of cell biology.

[57]  D. Tarin,et al.  Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? , 2005, Cancer research.

[58]  T. Guerrero,et al.  Extrapleural pneumonectomy followed by IMRT: Results of a phase I/II study , 2005 .

[59]  E. Pasquale,et al.  Eph receptors and ephrin ligands: embryogenesis to tumorigenesis , 2000, Oncogene.

[60]  H. Kindler,et al.  New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. , 2002, Seminars in oncology.

[61]  K. Rosenzweig,et al.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. , 2001, The Journal of thoracic and cardiovascular surgery.

[62]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[63]  A. Ryan,et al.  Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice , 2004, Clinical Cancer Research.

[64]  J. Gutterman,et al.  Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. , 1996, Oncogene.

[65]  M. Nguyen,et al.  Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. , 2005, Blood.